107.255 articles found

Neuroleptic-Induced Parkinsonism in Elderly Patients Diagnosed With Psychotic Major Depression and Dementia of the Alzheimer Type.

Sweet RA, Mulsant BH, Pollock BG, Rosen J, Altieri LP.

Am J Geriatr Psychiatry · 1996-09-01

DOI: 10.1097/00019442-199622440-00005PMID: 28530968

ORAL PHARMACEUTICAL FAST-DISPERSING COMPOSITION OF DOPAMINE AGONIST AND METHOD FOR TREATMENT OF PARKINSON'S DISEASE

Check source for author details

· 1996-08-16

ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING PARKINSON'S DISEASE USING SAID COMPOSITION

JOHNSON EDWARD STEWART, CLARKE ANTHONY, GREEN RICHARD DAVID.

· 1996-08-16

Propofol-induced dyskinesias in Parkinson's disease.

Krauss JK, Akeyson EW, Giam P, Jankovic J.

Anesth Analg · 1996-08-01

DOI: 10.1097/00000539-199608000-00037PMID: 8694329

Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease.

Morens DM, Grandinetti A, Davis JW, Ross GW, White LR, Reed D.

Am J Epidemiol · 1996-08-01

DOI: 10.1093/oxfordjournals.aje.a008941PMID: 8712197

(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors.

Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H, Whitten JP, Adams P, Chavez-Noriega L, Correa LD, Crona JH, Mahaffy LS, Menzaghi F, Rao TS, Reid R, Sacaan AI, Santori E, Stauderman KA, Whelan K, Lloyd GK, McDonald IA.

J Med Chem · 1996-08-01

DOI: 10.1021/jm960328wPMID: 8765504

Breakthrough panic after amantadine treatment in a Parkinson's disease patient.

Noveske FG.

J Clin Psychiatry · 1996-08-01

PMID: 8752025

Deprenyl and levodopa and Parkinson's disease progression.

Fowler JS, Fazzini E, Volkow ND.

Ann Neurol · 1996-08-01

DOI: 10.1002/ana.410400228PMID: 8773616

Deprenyl in Parkinson's disease.

Korczyn AD, Nisipeanu P.

Ann Neurol · 1996-08-01

DOI: 10.1002/ana.410400229PMID: 8773617

Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease.

Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB.

Biochim Biophys Acta · 1996-08-01

DOI: 10.1016/0925-4439(96)00020-8PMID: 8781534

Day-to-day demands of Parkinson's disease.

Habermann B.

West J Nurs Res · 1996-08-01

DOI: 10.1177/019394599601800403PMID: 8797365

[Parkinson syndrome after CO poisoning. Unexpected late manifestation and favorable prognosis].

Garrels L, Folkerts H.

Nervenarzt · 1996-08-01

DOI: 10.1007/s001150050041PMID: 8805114